- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03783884
Protokol srovnávající dočasnou transvenózní stimulaci bránice se standardní péčí při odvykání od mechanické ventilace (RESCUE 3)
Randomizovaná, řízená, otevřená, multicentrická klinická studie k vyhodnocení bezpečného a efektivního výkonu systému stimulační terapie bránicí plicní stimulace u pacientů, kterým se nepodařilo odstavit se od mechanické ventilace.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Angers, Francie, 49933
- CHU Angers
-
Montpellier, Francie, 34295
- CHU Montpellier
-
Paris, Francie, 75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg, Francie, 67091
- CHU Strasbourg
-
-
-
-
-
Berlin, Německo, 10117
- Berlin Charite Mitte
-
Essen, Německo, 45276
- KEM Essen
-
Löwenstein, Německo, 74245
- SLK Löwenstein
-
Nuremberg, Německo, 90419
- Nürnberg Klinikum Nord
-
Schmallenberg, Německo, 57392
- FKKG Schmallenberg
-
Solingen, Německo, 42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Německo, 17475
- Universitätsmedizin Greifswald
-
-
-
-
California
-
Stanford, California, Spojené státy, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32610
- University of Florida, Shands
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60612
- Rush University Medical Center
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, Spojené státy, 60612
- U of Illinois at Chicago
-
Hines, Illinois, Spojené státy, 60141
- Edward Hines VA Hospital
-
Maywood, Illinois, Spojené státy, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- University of Louisville
-
-
Massachusetts
-
Burlington, Massachusetts, Spojené státy, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood, New Jersey, Spojené státy, 07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267
- University of Cincinnati
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Spojené státy, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Spojené státy, 02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia, South Carolina, Spojené státy, 29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84132
- University of Utah
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Ostatní jména:
|
|
Žádný zásah: Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Successful Weaning
Časové okno: Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
Časové okno: 30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
Časové okno: Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
Časové okno: Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
Časové okno: Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
Časové okno: 30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
Časové okno: Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
Časové okno: Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
Časové okno: through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
Časové okno: through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- P-300
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .